Tue, 16th Sep 2014 17:28
** Biotechnology company's shares up 3 pct at$13.94
** U.S. FDA approves oral therapy to treat opioid-inducedconstipation, co-developed with AstraZeneca Plc
** The drug will be sold under the trade name Movantik, andbe launched in the first half of 2015, the companies said
** Up to Monday's close, stock had gained about 19 pct thisyear
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...
(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...
Astrazeneca (AZN)